OBJECTIVE: To assess the efficacy and safety of the novel @entity2178 antagonist @entity9885 medoxomil in @entity1 with mild to moderate @entity101 , using a meta-analysis of the combined database from seven US and European clinical trials. DESIGN: Studies were randomized, double-blind, placebo-controlled and dose-finding (2.5-80 mg), with treatment duration of 6-52 weeks. SETTING: Hospital outpatient clinics. @entity1 POPULATION: A total of 3,095 @entity1 in the safety population and 3,055 @entity1 in the intent-to-treat (efficacy) population. METHODS: All studies used conventional sphygmomanometry for blood pressure measurements at trough (end of the dosing interval). Three studies also used 24-h ambulatory blood pressure monitoring for the principal efficacy evaluations. MAIN OUTCOME MEASURES: Percentage of @entity1 achieving diastolic blood pressure ( @entity11559 ) < or = 90 mmHg or decrease > or = 10 mmHg (responder rate), percentage of @entity1 achieving a target @entity11559 < or = 90 mmHg or target systolic blood pressure (SBP) < or = 140 mmHg (normalization rate), and mean decrease in @entity11559 from baseline to last visit. RESULTS: Efficacy variables tended to be dose related up to the 40 mg dose level. All @entity9885 medoxomil doses were statistically significantly more effective than placebo for responder rate, @entity11559 and SBP normalization rates, and mean decrease in @entity11559 . A clinically relevant decrease of > or = 5 mmHg from baseline in sitting @entity11559 was also observed at doses of 20 mg and above after correction for placebo effect The safety profile of @entity9885 medoxomil was similar to that of placebo and was not dose related. CONCLUSIONS: @entity15632 was safe and highly effective in lowering blood pressure in @entity1 with mild to moderate @entity101 in these studies.

Blood pressure response, but not adverse event incidence, correlates with dose of XXXX antagonist.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENT'] @entity11559 :: ('CHEBI:35861', 'Chemical') :: ['DBP'] @entity101 :: ('MESH:D006973', 'Disease') :: ['essential hypertension'] @entity2178 :: ('183', 'Gene') :: ['angiotensin II'] @entity15632 :: ('MESH:C097933', 'Chemical') :: ['Olmesartan medoxomil'] @entity9885 :: ('MESH:C437965', 'Chemical') :: ['olmesartan']
@entity2178 :: (183,Gene) :: ['angiotensin II']
